Enanta Pharmaceuticals (ENTA) Capital Expenditures (2012 - 2026)

Enanta Pharmaceuticals has reported Capital Expenditures for 15 years, with the latest figure at $15000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures fell 99.41% year-over-year to $15000.0; the trailing twelve-month figure through Mar 2026 stood at $1.8 million (down 93.39% YoY), and the FY2025 full-year result was $12.9 million, down 28.15% from the prior year.
• Capital Expenditures for Q1 2026 stood at $15000.0, down from $143000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $11.5 million in Q3 2024, with the low at -$9.9 million in Q2 2025.
• Historically, Capital Expenditures has averaged $2.4 million across 5 years, with a median of $1.7 million in 2024.
• Annual changes were most pronounced in 2022 — Capital Expenditures surged 6760.87% — and 2025, when it slumped 349.61%.
• Enanta Pharmaceuticals' Capital Expenditures stood at $3.2 million in 2022, then slumped by 75.06% to $787000.0 in 2023, then jumped by 1011.18% to $8.7 million in 2024, then tumbled by 98.36% to $143000.0 in 2025, then plunged by 89.51% to $15000.0 in 2026.
• The last three Capital Expenditures figures came in at $15000.0 (Q1 2026), $143000.0 (Q4 2025), and $11.5 million (Q3 2025), per Business Quant data.